Shots:

• The P-III trial (ADORING 2) evaluating topical Vtama (1%) vs vehicle in a ratio (2:1) in pediatrics aged ≤2yrs. and adult patients with AD
• The results showed that 46.4% vs 18.0% of patients treated with Vtama cream achieved the 1EPs of a vIGA-AD of clear (0) or almost clear (1) with a 2-grade improvement from baseline @8wk., 59.1% vs 21.2 % achieved the 2EPs of the proportion of patients with ≥75% improvement in EASI, 52.8% vs 24.1% of patients aged ≥12yrs. with a baseline PP-NRS score ≥4 achieved a ≥4-point reduction in the PP-NRS @8wk.
• AEs were mild to mod. with a low study discontinuation rate due to AEs (1.5% vs 3.0%) & no safety or tolerability signals were reported. Vtama, a novel aryl hydrocarbon receptor agonist cream & was approved in the US for the topical treatment of PsO in adults

Ref: Dermavant | Image: Dermavant

Related News:- Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults